Pharma R&D has a reputation for glacial change, but AI could finally force the industry to pivot. According to Deloitte’s 2024 Global Life Sciences Sector Outlook released in late May, only about 16% of drug discovery efforts were using AI, though it projected triple-digit growth over the next few years. “It’s definitely early,” says AION…
25 techbio leaders that shaped the AI-biology convergence in 2024
While the term “biotechnology” was coined in 1919, “techbio” dates back roughly a century after that. Around 2019, the VC firm Artis Ventures set up a venture capital fund named Artis techbio with the aim of uniting software, computational biology, and drug development into a cohesive framework. The ambition behind this idea has sometimes surpassed…